AlphAIAlphAI — Financial news for AI agents
TradingViewMAY 163 min read$CGEN

Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview

Compugen Ltd is expected to report a loss of 7 cents per share. This earnings preview provides a brief outlook on the company's financial performance.

Original reporting
TradingView · Refinitiv
Published May 16, 2026, 2:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 16, 2026, 2:31 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Compugen Ltd expected to post a loss of 7 cents a share - Earnings Preview — source image
Source · TradingView
Decision brief

The 30-second read

$CGENBearishHigh
01

Why it matters

The earnings forecast indicates challenges ahead, possibly due to R&D setbacks or market conditions.

02

Market read

High relevance for biotech investors; sector sentiment may be affected.

03

What to watch

Potential positive catalysts such as upcoming product approvals or partnerships that could offset earnings concerns.

Relevance 6/10Timing: Immediate, as earnings release is imminent or has just occurred.

Background

Compugen Ltd operates in the biotech/life sciences sector, with recent developments including pipeline updates and strategic collaborations.

Company-level read

Ticker impact

$CGENBearishHigh confidence
Context

High relevance due to direct impact on company's financials and bearish sentiment.

Expected impact

Moderate decline expected in the near term, approximately 5-8% based on earnings disappointment.

Evidence & confidence

Earnings reports significantly influence stock price, and a predicted loss coupled with bearish sentiment supports a downward movement.

Market effects

Sector

Potential negative sentiment in the biotech/life sciences sector due to earnings outlook.

Regional

Limited, as company-specific news; regional effects minimal.

Global

Low, as it pertains to a single company's earnings.

Counterpoint

What could challenge this read

The company might have already priced in the expected loss, and actual results could be better than forecast, leading to a rebound.

Key entities

  • Company
    Compugen Ltd

    A biotech company focused on immunotherapy and cancer treatment.

Read at source← All news

Related articles

AUG 3
$CGENMed

Compugen Reports Second Quarter 2026 Results

Compugen Ltd. (NASDAQ: CGEN) reported Q2 2026 results and a corporate update. The MAIA-ovarian trial of COM701 is progressing, with median progression-free survival interim data expected in Q1 2027. Partner AstraZeneca presented GEMINI-Hepatobiliary overall survival data for rilvegostomig (median 16.8 months). Cash was about $125.3M, funding operations into 2029. Q2 revenue was ~$2.6M vs ~$1.3M in 2025; net loss ~$7.0M.

prnewswire.com7 min
OCT 28
$BBAIHigh

Cantor Fitzgerald cuts BigBear.ai stock price target on execution concerns

Cantor Fitzgerald reduced its price target on BigBear.ai (BBAI) to $3.00 from $4.00, citing execution concerns. The stock is down 65% over the past year. BigBear.ai reported Q3 revenue of $43.6M, up 31.5% YoY, but adjusted EBITDA was negative $9.1M. The company raised its fiscal 2026 revenue guidance to $150M-$165M. Analysts do not expect profitability this year, with EPS forecast at -$0.03 for FY2026.

investing.com2 min
OCT 28
$MRNAHigh

Why is Moderna stock rebounding today?

Moderna (MRNA) stock rose 3.1% to $214.41 after positive Phase 3 trial data for its cancer vaccine was presented, showing a 42% reduction in melanoma recurrence risk. Piper Sandler raised its price target to $230, countering a prior downgrade. Analysts remain divided, with a consensus 'Hold' rating. The stock had fallen 18% the prior week. Earnings are due November 6.

investing.com2 min